Calculators & Tools
Interactive tools grounded in the scientific literature to support educational understanding of peptides. They do not replace professional evaluation.
Notice — Educational Use OnlyThese tools present calculations and data drawn from the scientific literature for educational purposes. They do not constitute medical prescription, diagnosis, therapeutic guidance or a recommendation of use. Individualizing any intervention requires evaluation by a qualified healthcare professional.
⚗️ Reconstitution Calculator
Compute the resulting concentration when adding solvent to a lyophilized peptide, as described in the literature.
Concentration—mg/mL
Concentration—µg/µL
Total in vial—µg
Fill the fields above to see the volume matching a dose described in the literature.
📐 Unit Converter — GH
Converts Growth Hormone values between units used in the literature (WHO 98/574 standard).
Result—mIU/L
WHO 98/574 · 1 µg/L = 3 mIU/L · 1 nmol/L ≈ 22 ng/mL
📚 Examples of Doses Described in the Literature
The ranges below are EXAMPLES drawn from published studies (animal models, clinical trials or reports), shown for educational purposes only. They are NOT dose recommendations. Many are research extrapolations; most peptides are not approved for routine human use. Any clinical decision requires a licensed professional.
| Peptide | Range described in studies | Source |
|---|---|---|
| Ipamorelin · full page | 100–300 mcg per administration; 1–3×/day in GH-deficit models (studies). | PMID 9849822 |
| CJC-1295 · full page | no-DAC: 100–200 mcg; DAC: 1–2 mg/week (combination studies). | PMID 16822960 |
| BPC-157 · full page | animal models ~10 mcg/kg; human extrapolations in reports: 200–500 mcg. | PMID 30915550 |
| TB-500 · full page | equine 5–10 mg; human extrapolations 2–5 mg (exploratory literature). | PMID 21241358 |
| GHK-Cu · full page | topical 0.5–3% in formulations; subcutaneous (exploratory) 1–2 mg. | PMID 26110226 |
| PT-141 · full page | FDA-approved (HSDD): 1.75 mg SC on-demand; studies 1–2 mg IN/SC. | PMID 30256986 |
| Tesamorelin · full page | FDA-approved (HIV lipodystrophy): 2 mg SC once daily. | PMID 20212524 |
| Kisspeptin · full page | Kisspeptin-54: IV infusion 0.24 nmol/kg/h; bolus 1–9.6 nmol/kg (studies). | PMID 19036868 |
| Semaglutida · full page | obesity (STEP trials): target 2.4 mg/week SC, with gradual titration. | PMID 33567185 |
| Tirzepatida · full page | obesity (SURMOUNT trials): titration up to 10–15 mg/week SC. | PMID 35658024 |